Most organizations trying out generative AI—a full 95%—are failing to receive a measurable return on the pilot investment. 

If three sticking points aren’t unstuck soon, older Americans won’t benefit much by the 1,000+ medical devices that, as of 2025, are both equipped with AI and cleared by the FDA. 

A new generation of AI-native researchers is leading the way in the war on cancer. This next crop of scientists is AI-native, interdisciplinary—and comfortable challenging assumptions. 

The roots of medicine are in the promotion of human welfare, aka humanitarianism. Healthcare AI can either degrade or reinforce this heritage. Who picks the path? 

New ACC/AHA recommendations encourage clinicians to take a proactive approach when managing patients with elevated or high blood pressure. The inclusion of renal denervation in this document represents clear progress for a relatively new technology.

If not for off-limits data, AI might have a decent shot at curing cancer. 

Nurse leaders seeking AI acceptance from those they lead would do well to apply psychological insights along with technical tips.  

Treatment with the device is consistently safe, but researchers still think more data is required before reaching any conclusions about its efficacy.